ATHOS KG, AT Impf GmbH and Thomas Maier report beneficial ownership of 101,702,378 Ordinary Shares of BioNTech. This stake represents 40.2% of the class based on 252,884,261 ordinary shares outstanding as of March 31, 2026, per the issuer's disclosure. The holdings are reported on Amendment No. 6 to a Schedule 13G/A and reflect shared voting and dispositive power through ATHOS-related entities.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed by ATHOS group; governance implications depend on holder intent.
The filing shows 101,702,378 shares with shared voting and dispositional power held by ATHOS KG/AT Impf GmbH and Thomas Maier, equal to 40.2% of outstanding shares as of March 31, 2026. The report is a Schedule 13G/A amendment, which typically signals passive ownership reporting rather than an active 13D control intent.
Key dependencies include whether ATHOS maintains passive status and any future amendments; subsequent filings would indicate changes in voting arrangements or intent. Cash-flow treatment and any plans for disposition are not stated in the provided excerpt.
Key Figures
Shares beneficially owned:101,702,378 sharesPercent of class:40.2%Shares outstanding (issuer):252,884,261 shares
3 metrics
Shares beneficially owned101,702,378 sharesReported by ATHOS KG/AT Impf GmbH/Thomas Maier on Amendment No. 6
Percent of class40.2%Calculated using outstanding shares as of <date>March 31, 2026</date>
Shares outstanding (issuer)252,884,261 sharesIssuer-reported outstanding shares as of <date>March 31, 2026</date>
"Amendment No. 6 to a Schedule 13G/A is being jointly filed"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
shared dispositive powerregulatory
"Shared Dispositive Power 101,702,378.00"
Joint Filing Agreementregulatory
"Reporting Persons have entered into a Joint Filing Agreement, dated February 11, 2022"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
BioNTech SE
(Name of Issuer)
Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
(Title of Class of Securities)
09075V102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
09075V102
1
Names of Reporting Persons
ATHOS KG
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
GERMANY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
101,702,378.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
101,702,378.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
101,702,378.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
40.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
09075V102
1
Names of Reporting Persons
AT Impf GmbH
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
GERMANY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
101,702,378.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
101,702,378.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
101,702,378.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
40.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
09075V102
1
Names of Reporting Persons
Thomas Maier
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
GERMANY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
101,702,378.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
101,702,378.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
101,702,378.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
40.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BioNTech SE
(b)
Address of issuer's principal executive offices:
AN DER GOLDGRUBE 12, MAINZ, GERMANY, 55131.
Item 2.
(a)
Name of person filing:
This Amendment No. 6 to Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH and Thomas Maier, each of the foregoing, a "Reporting Person," and collectively, the "Reporting Persons." The sole member of AT Impf GmbH is ATHOS KG and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. Thomas Maier is the general partner (komplementar) of ATHOS KG. The limited partners (kommanditisten) of ATHOS KG are members of the families of Thomas and Andreas Strungmann.
The Reporting Persons have entered into a Joint Filing Agreement, dated February 11, 2022, which was attached as Exhibit 1 to Amendment No. 2 to Schedule 13G filed by the Reporting Persons, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is Bergfeldstrasse 9
83607 Holzkirchen.
(c)
Citizenship:
ATHOS KG is a German limited partnership (Kommanditgesellschaft); AT Impf GmbH is a German limited liability company (Gesellschaft mit beschrankter Haftung); and Mr. Maier is a citizen of Germany.
(d)
Title of class of securities:
Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
(e)
CUSIP No.:
09075V102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the responses to Item 9 on the attached cover pages.
(b)
Percent of class:
See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission on May 5, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the responses to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See the responses to Item 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See the responses to Item 8 on the attached cover pages.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See responses to Item 2(a) and Item 4.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See responses to Item 2(a) and Item 4.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
ATHOS KG, AT Impf GmbH and Thomas Maier report beneficial ownership of 101,702,378 shares, equal to 40.2% of the class based on 252,884,261 outstanding as of March 31, 2026.
How was the 40.2% ownership calculated in the filing?
The 40.2% figure was calculated using 252,884,261 ordinary shares outstanding as reported by the issuer as of March 31, 2026, per the filing's Item 4 disclosure.
Which entities hold the shares reported in the Schedule 13G/A?
Reported holders are ATHOS KG, AT Impf GmbH (ATHOS KG is sole member) and Thomas Maier (general partner), with shared voting and dispositive power over the 101,702,378 shares.
Does this Schedule 13G/A indicate ATHOS seeks control of BioNTech?
The filing is an amendment to a Schedule 13G/A, which reports beneficial ownership; it does not itself state an intent to acquire control. The excerpt does not disclose any change in intent or control-seeking actions.
Where is the outstanding share count sourced from in the filing?
The outstanding share count of 252,884,261 is cited from the issuer's Form 6-K, which the filing references as reporting the outstanding shares as of March 31, 2026.
